Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2019 to Jul 2024
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs to
treat diseases of aging such as Type 2 Diabetes, announced today that
Leonard P. Guarente, PhD, Novartis Professor of Biology at the
Massachusetts Institute of Technology, has signed a new, exclusive
consulting agreement with Sirtris Pharmaceuticals. Dr. Guarente first
joined Sirtris’ Scientific Advisory Board as
Co-Chair in November 2007.
“We are delighted to have deepened our
relationship with Professor Guarente through this new agreement,”
says Christoph Westphal, MD, PhD, Chief Executive Officer and Vice Chair
of Sirtris Pharmaceuticals. “Professor
Guarente, a recognized founder of the sirtuin field and Co-Chair of our
Scientific Advisory Board, provides critical guidance to our Scientific
Advisory Board and his ideas and research shape our therapeutic efforts.”
“I am proud to serve as Co-Chair of Sirtris’
Scientific Advisory Board, and to be working with Sirtris alone in all
sirtuin related fields,” says Leonard P.
Guarente, PhD, the Novartis Professor of Biology at the Massachusetts
Institute of Technology. “Sirtris has built a
Scientific Advisory Board with every key opinion leader in the sirtuin
field, and is well-positioned to develop therapeutics that target this
family of genes for the treatment of diseases of aging.”
“Lenny has made and is making defining
contributions to the sirtuin field,” says
David Sinclair, PhD, Co-Founder of Sirtris and Associate Professor of
Pathology at Harvard Medical School. “Through
our ongoing collaborations, we and our Scientific Advisory Board members
hope to further define the therapeutic avenues in this field,”
added Sinclair, who also Co-Chairs Sirtris’
Scientific Advisory Board.
Sirtris recently announced positive Phase 1b clinical trial results with
drug candidate SRT501, a proprietary formulation of resveratrol, in
patients with Type 2 Diabetes. SRT501, which targets the SIRT1 enzyme,
was found to be safe and well-tolerated, and significantly lowered
glucose at the two-hour time point in an oral glucose tolerance test
conducted as part of the 28 day Phase 1b trial of patients with Type 2
Diabetes who were naïve to treatment. Sirtris’
new chemical entities (NCEs) activate SIRT1 and are chemically distinct
from and 1000 times more potent, in vitro, than resveratrol. The NCEs
have been shown to lower glucose and improve insulin sensitivity in
predictive preclinical models of Type 2 Diabetes. SIRT1 activators have
the potential to be frontline therapy for Type 2 Diabetes.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small molecule
drugs with the potential to treat diseases associated with aging,
including metabolic diseases such as Type 2 Diabetes. Our drug
candidates are designed to mimic certain beneficial health effects of
calorie restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that the
Company believes control the aging process. The company's headquarters
are in Cambridge, Massachusetts.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, the potential therapeutic
effects of SIRT1 activators such as SRT501 and NCEs for diseases of
aging such as Type 2 Diabetes:, the progress and results of pre-clinical
and clinical studies of SIRT1 activators, and the potential of sirtuin
modulators to receive regulatory approval. These forward-looking
statements about future expectations, plans and prospects of Sirtris
Pharmaceuticals involve significant risks, uncertainties and
assumptions, including risks related to the lack of results that would
provide a basis for predicting whether any of the Company's product
candidates will be safe or effective, or receive regulatory approval,
the possibility that results of pre-clinical studies are not necessarily
predictive of clinical trial results, the Company's potential inability
to initiate and complete pre-clinical studies and clinical trials for
its product candidates, the fact that none of the Company's product
candidates has received regulatory approvals, the potential inability of
the Company to gain market acceptance of the Company's product
candidates, and those other risks factors that can be found in the
Company's filings with the Securities and Exchange Commission. Actual
results may differ materially from those Sirtris Pharmaceuticals
contemplated by these forward-looking statements. Sirtris
Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or events or
circumstances that occur after the date of this release.